Japan Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of R/R DLBCL Announced June 23, 2026
FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat indolent non-Hodgkin lymphoma June 2, 2026
Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma June 2, 2026
Positive 12-Month Follow-Up Data from Ph 2b CLOVER WaM Study Shows Durable Responses & Efficacy of Iopofosine I 131 in R/R Waldenström Macroglobulinemia May 12, 2026
DMC recommends halting Ph 3 FLASH2 trial of HyBryt (Synthetic Hypericin) in the treatment of CTCL patients post interim efficacy analysis May 6, 2026
Journal of Clinical Oncology Publishes Final Results of Duvelisib PRIMO Ph 2 Trial in R/R Peripheral T-cell Lymphoma May 6, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
Opdivo combination regimens received FDA approval for previously untreated, Stage III or IV cHL and EC approval in R/R cHL after one prior line of therapy March 24, 2026
Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
Type A meeting with FDA scheduled to discuss the CRL to the BLA for tabelecleucel (tab-cel) March 17, 2026
FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL March 10, 2026
First patient dosed in the PiNACLE – H2H Ph 3 trial of rondecabtagene autoleucel (ronde-cel or LYL314) vs liso-cel or axi-cel in 2L R/R LBCL February 17, 2026
